Seeking Alpha
View as an RSS Feed


View DoctoRx's Articles BY TICKER:
  • Deflationary Pressures Post-QE 3 Make Bonds Interesting Again For Income And Potential Capital Gains
    Tue, Nov. 24 AAPL, AMZN, DBC 62 Comments
  • Biotechs Go Low-Fat: Relevance To Amgen, Regeneron, The Medicines Company And Isis
    Thu, Nov. 19 AMGN 60 Comments
  • The Strengthened Case For 'Risk Off': Liking Extra Cash And Some Other 'Value' Assets
    Mon, Nov. 16 GILD 153 Comments
  • Isis Pharmaceuticals Moves Closer To A Durable Success
    Wed, Nov. 11 ISIS 63 Comments
  • Has Celgene's Stock Been Beaten Up Enough?
    Mon, Nov. 9 CELG 90 Comments
  • Gilead - Good Newsflow Accelerates; All-Time Highs Now Achievable
    Fri, Nov. 6 GILD 213 Comments
  • Regeneron Accelerates In Q3: A Review Of The Quarter, The Company, And A Look Ahead
    Wed, Nov. 4 REGN 65 Comments
  • Biotechs Blast Off: Could The 1999 Scenario Be In Play?
    Editors' Pick  • Tue, Nov. 3 GILD 140 Comments
  • Revance: Trying To Bring Two Different Versions Of A 'Better Botox' To Market
    Editors' Pick  • Mon, Nov. 2 RVNC 24 Comments
  • Amgen: Q3 Review; Comments On Repatha And Corlanor Launches And On The Pipeline
    Thu, Oct. 29 AMGN 35 Comments
  • Gilead's Q3 Beats, The Street Shrugs: Why I'm Happy To Stay The Course
    Editors' Pick  • Wed, Oct. 28 GILD 224 Comments
  • Why Commodities May Be Ready To Drop Again: Implications For Bonds And Biotechs
    Editors' Pick  • Tue, Oct. 27 CELG 71 Comments
  • Implications For Gilead Of The Problems With AbbVie's Competitive Hepatitis C Product
    Editors' Pick  • Thu, Oct. 22 GILD 415 Comments
  • Basic Problems With Valeant's Valuation, With Comments On Recent News
    Editors' Pick  • Thu, Oct. 22 VRX 104 Comments
  • Biogen Reports Q3: Review And Analysis
    Wed, Oct. 21 BIIB 45 Comments
  • Is Large Cap Biotech One Of The Few Market Sectors With An Attractive Valuation?
    Editors' Pick  • Tue, Oct. 20 GILD 97 Comments
  • An Analysis Of J&J's Issues And Thoughts On Potential Ways To Maximize Shareholder Value
    Editors' Pick  • Wed, Oct. 14 JNJ 49 Comments
  • Biogen Drops Again: A Reassessment Of The Bull And Bear Investment Cases
    Editors' Pick  • Tue, Oct. 13 BIIB 46 Comments
  • An Analysis Of Allergan
    Editors' Pick  • Sat, Oct. 10 AGN 98 Comments
  • Did Express Scripts Just Give A 'Buy' Recommendation On Amgen And Regeneron?
    Editors' Pick  • Wed, Oct. 7 AMGN 55 Comments
  • The Case For A Biotech-Bonds Barbell Strategy: Focus On Several Junior Biotech Stocks
    Editors' Pick  • Mon, Oct. 5 AAPL, ALNY, ALXN 30 Comments
  • More Carnage In Junior Biotechs: General Comments With Focus On Opko And Acceleron
    Editors' Pick  • Wed, Sep. 30 OPK, XLRN 92 Comments
  • Biotechs Battered: Comments On All 6 Major Biotech Stocks
    Editors' Pick  • Mon, Sep. 28 ABBV, ABT, AMGN 288 Comments
  • Reassessing Biotech Stocks After The Renewed Sell-Off: Focus On Regeneron
    Tue, Sep. 22 REGN 137 Comments
  • Gilead Provides An Update: Review And Analysis Of Wednesday's Q&A
    Editors' Pick  • Thu, Sep. 17 GILD 120 Comments
  • Mr. Market Errs: Apple Is Unlikely To Be Stopped In Its Rise To Further Heights
    Thu, Sep. 10 AAPL 200 Comments
  • Amgen Vs. Regeneron In The PCSK9i War, With Comments On Competitive Threats
    Thu, Sep. 10 AMGN 54 Comments
  • A Review Of NantKwest, Dr. Soon-Shiong's Immuno-Oncology Company
    Tue, Sep. 8 NK 39 Comments
  • Review Of Biotechs (Part 3 Of 3): Focus On Small-Caps; Initiating Coverage Of OPKO
    Editors' Pick  • Wed, Sep. 2 OPK 85 Comments
  • Biotech Review (Part 2 Of 3): New Coverage Of Some Mid-Caps With Update On Intercept
    Mon, Aug. 31 ICPT 38 Comments
  • Comments On The Market Correction; Focus On Biotechs: Large Caps
    Editors' Pick  • Wed, Aug. 26 REGN 114 Comments
  • Gilead's Pipeline, Part 3, With Summary Comments
    Editors' Pick  • Mon, Aug. 24 GILD 127 Comments